Program
Anti-PSMA/CD3 Protease-activated T-cell Engager JANX007
Its studies are mostly in Prostatic Neoplasms, Castration-Resistant · Prostatic Neoplasms, led by Janux Therapeutics.
Furthest: phase 1, since Aug 25, 20222 company-led studies, 2 open or runningNext primary completion: Jul 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Janux Therapeutics | 22 open or running | phase 1since Aug 25, 2022 | Aug 25, 2022 | Jul 2027phase 1 · NCT05519449 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 25, 2022First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT05519449 · 272 planned · United States, Australia, Spain
- Sep 4, 2026Phase 1 study in Prostatic NeoplasmsNCT07813637 · 110 planned · United States
Ahead
- Jul 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT05519449
- Jul 2029Primary completion: phase 1 study in Prostatic NeoplasmsNCT07813637
TargetBeta
FOLH1 →read by rule
“A protease-activated, masked T-cell engager (TCE) composed of a prostate-specific membrane antigen (PSMA)-binding domain and a CD3-binding domain ”NCIt, by rule
Other programs on FOLH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| flotufolastat F 18rule | Bracco | phase 4 | 7 |
| piflufolastatrule | Lantheus | phase 4 | 5 |
| abefolastat tesaroxetan CU-64rule | clarity-pharmaceuticals-ltd | phase 3 | 5 |
| gallium 68 PSMA-11rule | Novartis | phase 3 | 4 |
| Lutetium Lu 177 Ludotadipeprule | futurechem | phase 3 | 3 |
| Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401 | Johnson & Johnson | phase 3 | 2 |
| Lutetium Lu 177 NYM032rule | Norroy Bioscience | phase 3 | 2 |
| actinium AC-225 vipivotide tetraxetan | Novartis | phase 3 | 2 |
| HRS-4357 | Jiangsu HengRui Medicine | phase 3 | 2 |
| zadavotide guraxetan | AstraZeneca | phase 2 | 4 |
| AB-001rule | frontier-biotechnologies-inc | phase 2 | 3 |
| olsutamigrule | Regeneron Pharmaceuticals | phase 2 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07813637Prostatic Neoplasms · United States | 1 | Recruiting | Jul 2029 | 110 |
| NCT05519449Prostatic Neoplasms · United States, Australia, Spain | 1 | Recruiting | Jul 2027 | 272 |
How it is read
Names in the registry
- “JANX007”, 3 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, Castration-Resistant, 1 study
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.